AstraZeneca not materially affected by Daiichi Sankyo oncology supply review

12 articles · Updated · The Wall Street Journal · Apr 27

Citi analysts report that AstraZeneca’s sales, including oncology drugs Enhertu and Datroway, remain stable despite Daiichi Sankyo’s delayed fiscal 2026 results due to supply plan reviews.
Daiichi Sankyo’s review is linked to efforts to resolve manufacturing network issues, but is expected to have little or no impact on AstraZeneca’s oncology portfolio.
AstraZeneca shares rose 0.3% following the news, as analysts anticipate no significant disruption to its partnership with Daiichi Sankyo or to sales of key oncology drugs.

Can AstraZeneca's cancer drugs overcome manufacturing woes before rivals close the gap?

Will safety concerns for Roche's new drugs derail its post-blockbuster future?

Beyond big profits, are we ignoring the serious side effects of new blockbuster drugs?

Will Sanofi's €25 billion war chest finally solve its critical drug pipeline problem?

As weight-loss pills launch, will convenience or efficacy decide the Lilly vs. Novo battle?

A glove maker collapsed from war and scandal. Are its rivals next to fall or set to thrive?